Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muffly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen-Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai

Blood (2023) 141 (22): 2727–2737.

https://doi.org/10.1182/blood.2022018827

Published: 2023

Includes: Supplemental data

Journal Articles

Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals

Lu Cui, Cristabelle De Souza, Tristan Lerbs, Jessica Poyser, Clarissa Yu, Kerri Rieger, Sally Arai, Ryanne Brown, Judith A Shizuru, Antonia Maria Susanne Müller, Gerlinde Wernig

Blood (2022) 140 (Supplement 1): 272–273.

https://doi.org/10.1182/blood-2022-169789

Published: 2022

Journal Articles

Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease

Michelle Chin, Judith A. Shizuru, Lori Muffly, Parveen Shiraz, Laura J. Johnston, Robert Lowsky, Andrew R. Rezvani, Matthew J. Frank, Sushma Bharadwaj, Wen-Kai Weng, Robert S. Negrin, David B. Miklos, Sally Arai

Blood (2022) 140 (Supplement 1): 4788–4789.

https://doi.org/10.1182/blood-2022-165547

Published: 2022

Journal Articles

The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes

Blood (2022) 140 (Supplement 1): 12775–12777.

https://doi.org/10.1182/blood-2022-170877

Published: 2022

Journal Articles

Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 10371–10373.

https://doi.org/10.1182/blood-2022-170759

Published: 2022

Journal Articles

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Blood (2022) 140 (Supplement 1): 7545–7547.

https://doi.org/10.1182/blood-2022-165600

Published: 2022

Journal Articles

Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era

Shona Philip, Robert Lowsky, Laura J. Johnston, Sally Arai, Everett H. Meyer, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Surbhi Sidana, Wen-Kai Weng, Sushma Bharadwaj, Matthew J. Frank, David B. Miklos, Melody Smith, Lori Muffly, Vaibhav Agrawal

Blood (2022) 140 (Supplement 1): 4825–4827.

https://doi.org/10.1182/blood-2022-168546

Published: 2022

Journal Articles

Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study

Blood (2021) 138 (Supplement 1): 3885.

https://doi.org/10.1182/blood-2021-149306

Published: 2021

Journal Articles

Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells

Chiara F Magnani, Renier Myburgh, Norman F Russkamp, Steve Pascolo, Judith A Shizuru, Dario Neri, Markus G Manz

Blood (2021) 138 (Supplement 1): 2808.

https://doi.org/10.1182/blood-2021-145195

Published: 2021

Journal Articles

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

Blood (2021) 138 (Supplement 1): 554.

https://doi.org/10.1182/blood-2021-153074

Published: 2021

Journal Articles

Selective Targeting of Immune Modulatory Proteins to Mitigate Fibrosis and Inflammation in Sclerodermatous Graft-Vs-Host Disease

Lu Cui, Cristabelle De Souza, Tristan Lerbs, Jessica Poyser, Maryam Kooshesh, Atif Saleem, Kerri Rieger, Ryanne Brown, Bernice Kwong, Sebastian Fernandez-Pol, Sally Arai, Judith A Shizuru, Antonia MS Mueller, Gerlinde Wernig

Blood (2021) 138 (Supplement 1): 644.

https://doi.org/10.1182/blood-2021-151223

Published: 2021

Journal Articles

Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma

Christopher Lemieux, MD, Juliana Craig, BA, David Iberri, MD, Sally Arai, MD MS, Laura J. Johnston, MD, Robert Lowsky, MD FRCP, Lori S. Muffly, MD MS, Parveen Shiraz, MD, Michaela Liedtke, MD, Andrew R. Rezvani, MD, Matthew J. Frank, MD PhD, Wen-Kai Weng, MD PhD, Everett H Meyer, MD PhD, Judith A Shizuru, MD PhD, Robert S. Negrin, MD, David B. Miklos, MD PhD, Surbhi Sidana, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-137091

Published: 2020

Journal Articles

Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-142218

Published: 2020

Journal Articles

5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice

Andriyana K Bankova, MD, Wendy W Pang, MD PhD, Brenda J Velasco, Janel R Long-Boyle, PharmD, PhD, Judith A Shizuru, MD PhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139058

Published: 2020

Journal Articles

First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-137762

Published: 2020

Journal Articles

Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant

Christopher Lemieux, MD, Lori S. Muffly, MD MS, Sally Arai, MD MS, Andrew R. Rezvani, MD, Surbhi Sidana, MD, Laura J. Johnston, MD, Wen-Kai Weng, MD PhD, Parveen Shiraz, MD, Matthew J. Frank, MD PhD, Everett H Meyer, MD PhD, Judith A Shizuru, MD PhD, David B. Miklos, MD PhD, Robert S. Negrin, MD, Robert Lowsky, MD FRCP

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-134250

Published: 2020

Journal Articles

Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation

Olivier Veilleux, MD, Francisco Socola, MD, Sally Arai, MD MS, Robert Lowsky, MD FRCP, Judith A Shizuru, MD PhD, Parveen Shiraz, MD, Lori S. Muffly, MD MS, Laura J. Johnston, MD, Matthew J. Frank, MD PhD, Surbhi Sidana, MD, Everett H Meyer, MD PhD, Andrew R. Rezvani, MD, David B. Miklos, MD PhD, Robert S. Negrin, MD, Wen-Kai Weng, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136493

Published: 2020

Journal Articles

Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-138988

Published: 2020

Journal Articles

Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-142974

Published: 2020

Journal Articles

Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis

Juliana Craig, BA, Maria Iglesias, BS, Kristen Cunanan, PhD, Sally Arai, MD MS, Matthew J. Frank, MD PhD, Laura J. Johnston, MD, Robert Lowsky, MD FRCP, Everett H Meyer, MD PhD, David B. Miklos, MD PhD, Robert S. Negrin, MD, Andrew R. Rezvani, MD, Judith A Shizuru, MD PhD, Surbhi Sidana, MD, W-K Weng, MD PhD, Parveen Shiraz, MD, Lori S. Muffly, MD MS

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-141489

Published: 2020

NARROW

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals

Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease

The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes

Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era

Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study

Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

Selective Targeting of Immune Modulatory Proteins to Mitigate Fibrosis and Inflammation in Sclerodermatous Graft-Vs-Host Disease

Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma

Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity

5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice

First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency

Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant

Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation

Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study

Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants

Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only